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Dear Sirs,
Episodic ataxias (EAs) are rare neurological disorders char-
acterized by recurrent episodes of cerebellar ataxia with an 
imbalance of stance and gait, limb ataxia, dysarthria, and 
nystagmus, often triggered by physical or emotional stress, 
or alcohol and accompanied by nausea and vomiting (for 
review see [1, 2]). Currently, there are at least seven known 
subtypes of EA. Among them, EA1 and EA2 are clinically 
most relevant [2]. EA2 has its onset typically in adolescence, 
but some cases with a late onset have been reported [3]. EA2 
episodes generally last between minutes and hours, and are 
accompanied by migraine-like cephalgia in around 50% of 
patients [4]. EA 2 patients frequently develop slowly pro-
gressive interictal ataxia and distinct central ocular motor 
dysfunctions, e.g., mainly gaze-evoked or downbeat nys-
tagmus [4, 5]. EA2 is an inherited autosomal-dominant 
channelopathy, caused by pathogenic variants affecting the 
CACNA1A gene on chromosome 19p13, which encodes the 
alpha-1A subunit of the P/Q-type voltage-gated calcium 
channel (Cav2.1) [1, 6]. The latter is found ubiquitously in 
the nervous system with high expression levels in cerebellar 
Purkinje cells [7, 8]. EA2 shares molecular pathologic simi-
larities with spinocerebellar ataxia type 6 (SCA6), familial 
hemiplegic migraine (FHM) and epileptic encephalopathy, 
also carrying mutations in the CACNA1A gene. Typically, 
cases of FHM present with missense mutations, SCA6 with 
a C-terminal polyglutamine expansion and EA2 harbors 
point mutations resulting in premature stop codons as well 
as small or large deletions, insertions and missense muta-
tions [2]. During the last decades, an increasing number of 
CACNA1A variants have been described. Here, we report on 
a female patient with a novel pathogenic CACNA1A variant 
and give insights into the heterogeneous phenotypes within 
her family.
A 47-year-old white Caucasian female presented to our 
tertiary outpatient center with recurrent attacks of postural 
imbalance (no vertigo sensu stricto, no nausea or vomiting) 
with the feeling of falling forward, and an associated holoce-
phalic headache that began around the age of 15 years. The 
attacks occurred daily, most often in stressful situations and 
usually lasted for several hours. No other triggers were evi-
dent. By the time the patient presented to us, she felt perma-
nently dizzy and posturally unstable in between the attacks, 
rendering her dependent on regular help in her daily routine. 
There was no catamnestic report of seizures or syncopes.
Her clinical and neuro-ophthalmological examination 
revealed a cerebellar ocular motor dysfunction with bilateral 
horizontal gaze-evoked and rebound-nystagmus, saccadic 
pursuit in all directions, hypermetric horizontal and vertical 
saccades, reduced optokinetic nystagmus in all directions, 
and an most probably centrally impaired horizontal vestib-
ulo-ocular reflex bilaterally (video head-impulse test: gain of 
0.44 on the right and 0.35 on the left). Bithermal caloric test-
ing showed a central preponderance of left-beating nystag-
mus without spontaneous nystagmus (warm right – 3.8°/s, 
warm left + 22.9°/s, cold right 6.4°/s, cold left – 2.0°/s). 
Finger-to-finger following showed slightly hypermetric 
movements. Romberg’s test revealed an imbalance in tandem 
stance. Quantitative gait analysis with the GAITRite system 
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objectified a dynamic instability due to incipient impaired 
cerebellar postural adjustment. Cranial MRI showed several 
small supratentorial white matter lesions, but no distinct ver-
mian atrophy as is sometimes reported in EA 2 [1].
Genetic testing using next-generation sequencing and 
Sanger sequencing methods (i.e. enrichment of the genes 
CACNA1A, CACNB4, KCNA1, SCN2A, and SLC1A3, fol-
lowed by next-generation sequencing of coding exons as 
well as conserved parts of splice sites, and bioinformatic 
data analysis; hereby, in a first step an analysis of variants 
of the CACNA1A gene was performed prior to confirma-
tion of the variant by amplification with polymerase chain 
reaction and analysis by Sanger sequencing after a second, 
independent DNA extraction from the original blood sam-
ple) revealed a novel, heterozygous, pathogenic [9, 10] vari-
ant in exon 16 of the CACNA1A gene NM_001127221.1: 
[c2070_2071delinsGGAG, p.(Phe690Leufs*9)]. Deletions 
of cytosine and thymidine at position 2070–2071 and inser-
tion of four nucleotides at this position in exon 16 of the 
CACNA1A gene were identified. This leads to a frameshift 
during translation and to an early stop of protein synthesis at 
codon position 698 after the incorporation of eight changed 
amino acids. This variant has so far not been described in 
either the literature or has been observed in genome sequenc-
ing data from large-scale sequencing projects, e.g., ExAC 
(Exome Aggregation Consortium) or GnomAD (Genome 
Aggregation database). Other translational stop variants in 
the CACNA1A gene have been described in EA2 patients 
before [11, 12].
The same heterozygous CACNA1A variant was detected 
in three family members (Fig. 1) of our index patient, but 
the clinical phenotypes varied considerably. The 68-year-old 
mother is suffering from a slowly progressive imbalance of 
gait for almost 20 years. She negated cephalgia, episodic 
ataxia or vertigo. Her imbalance of gait is not accompanied 
by vegetative symptoms such as nausea or emesis. There are 
no triggers evident. Neurological examination of the ocu-
lomotor system revealed a gaze-evoked nystagmus to the 
right side. Romberg’s test showed omnidirectional swaying 
and finger-to-nose testing showed a slight dysmetria on both 
sides. Her gait was broad based and atactic. She has been 
taking acetazolamide (250 mg/days) for about 3 months with 
no significant amelioration of her symptoms. The 45-year-
old brother of our patient reported intermittent cephalgia, 
which started in his early childhood. He negated any recur-
rent attacks of postural imbalance, ataxia or vertigo. He does 
not take any medication regularly apart from NSAR tempo-
rarily. Neurological examination was without pathological 
findings. The 15-year-old nephew of our patient (her broth-
er’s son) has suffered from episodic attacks with imbalance 
Fig. 1  Pedigree of a German 
family carrying the novel patho-
genic heterozygous autosomal 
dominant CACNA1A variant. 
The newly identified heterozy-
gous variant NM_001127221.1: 
[c2070_2071delinsGGAG, 
p.(Phe690Leufs*9)], was found 
in four family members in three 
generations showing a hetero-
geneous phenotype. Legend: 
“Asterisk” = index patient, 
square = male, circle = female, 
filled symbol = genetically 
affected subject, blank sym-
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of gait, vertigo, and headache, typically lasting for several 
hours and triggered by stress since the age of 14 years. In 
between the attacks, he feels asymptomatic.
Pathogenic variants in the CACNA1A gene are known 
to lead to a broad clinical spectrum including EA2, SCA6, 
FHM and epileptic encephalopathy. Different variants usu-
ally tend to associate with different phenotypes, but some-
times family members harboring the same variant show a 
wide variability of the neurological manifestations [4, 13]. 
One further reason for the heterogeneous phenotype in our 
reported family could be incomplete penetrance. There is 
substantial evidence of intra-familial incomplete penetrance 
due to a pathogenic CACNA1A variant in the literature [4, 
14]. Nevertheless, an involvement of other genes and epige-
netic mechanisms cannot be excluded.
Therapeutic principles in patients with EA include medi-
cal treatment and physiotherapy, occupational therapy to 
preserve gait function, and speech therapy [15, 16]. In a ran-
domized placebo-controlled trial, it was shown that 4-ami-
nopyridine [17] is effective for the symptomatic treatment 
of EA2 (and downbeat nystagmus) [18]. Our patient did not 
respond sufficiently to the medical monotherapeutic treat-
ments of choice with 4-aminopyridine (Fampyra™ 20 mg/
days) and acetazolamide (250 mg–500 mg/days, discharged 
due to intolerable side effects such as paresthesia and kid-
ney dysfunction) [19]. The modified amino acid acetyl-dl-
leucine has been introduced as a drug for the symptomatic 
treatment of cerebellar disorders [20, 21]. Under reduction 
of 4-aminopyridine, the patient indicated significant aggra-
vation of her previously described symptoms. Consequently, 
we reestablished the well tolerated daily dose of 4-amino-
pyridine (20 mg/days). However, the effect of the medica-
tion was not fully satisfactory to the patient. Therefore, we 
applied ex juvantibus a combined individual therapeutic 
approach with 4-aminopyridine (Fampyra™ 20 mg/days) 
and acetyl-dl-leucine (5 g/days) in a second step. Over the 
ensuing observation period of 12 months, a subjectively 
relevant improvement of the patient’s daily performance, 
accompanied by a stabilization of objective clinical and 
functional measures such as videooculography (no deterio-
ration of ocular motor function), gait analysis (increase in 
velocity and step length) and ataxia scores (SARA score 4) 
could be observed interictally.
In conclusion, we identified a novel, pathogenic 
heterozygous CACNA1A variant NM_001127221.1: 
[c2070_2071delinsGGAG, p.(Phe690Leufs*9)] in a patient 
with EA2 and three other family members with a long undi-
agnosed history of the illness and a very heterogeneous 
phenotype across three generations of the family carrying 
the identical variant. The analysis of novel CACNA1A vari-
ants is an essential step in the in-depth characterization of 
EA2 patients. Our results might serve for molecular-genetic 
testing in similar patients, albeit future genetic analyses 
will most likely use high-throughput sequencing. From a 
therapeutic perspective after the patient did not respond 
sufficiently to standard treatment, a novel combination of 
4-aminopyridine (Fampyra™ 20 mg/days) to reduce the 
frequency of attacks, and acetyl-dl-leucine (5 mg/days) to 
symptomatically alleviate interictal cerebellar ataxia resulted 
in subjective improvement and no further progression of 
the disease to date. Such combined therapies might have 
an over-additive effect because of different modes of action 
and may open up a new treatment path in EA2 individuals, 
especially in cases where 4-aminopyridine or acetazolamide 
medication alone does not alter the course of the disease. 
However, further randomized placebo-controlled trials in 
episodic ataxias are needed.
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